# A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)

> **NCT06295796** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 18 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** MK-8527

## Key facts

- **NCT ID:** NCT06295796
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-20
- **Primary completion:** 2025-01-31
- **Final completion:** 2025-01-31
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06295796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06295796, "A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT06295796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*